Finoriq

Finoriq research workspace

Boundless Bio, Inc. (BOLD) SEC Filings & Filing Highlights

Boundless Bio, Inc., a clinical-stage oncology company, develops interrogating extrachromosomal. Review BOLD SEC filings, filing highlights, and disclosure activity on Finoriq.

Company Snapshot

Boundless Bio, Inc., a clinical-stage oncology company, develops interrogating extrachromosomal DNA (ecDNA) directed therapies for treating patients with oncogene amplified cancers. Its lead product candidate is BBI-940, an ecDNA-directed therapeutic candidate (ecDTx) that is in Phase 1/2 clinical trial in patients with estrogen receptor positive and human epidermal growth factor receptor 2 negative breast cancer, as well as patients with triple-negative breast cancer luminal androgen receptor subtype. The company was formerly known as Pretzel Therapeutics, Inc. and changed its name to Boundless Bio, Inc. in July 2019. Boundless Bio, Inc. was incorporated in 2018 and is headquartered in San Diego, California.

Company
Boundless Bio, Inc. (BOLD)
Ticker
BOLD
Market Cap
$55.5M
Latest Price
$2.47
Industry
Biotech & Pharma

Open insider transactions

Boundless Bio, Inc. (BOLD) Recent SEC Filing Highlights

Recent SEC filings, filing events, and disclosure highlights indexed for Boundless Bio, Inc. (BOLD).

EventFormDate
Boundless Bio and Serapha Bio Announce Merger Agreement and $230 Million Concurrent Private Pla...Boundless Bio and Serapha Bio Announce Merger Agreement and $230 Million Concurrent Private Placement8-K8.012026-06-23
Boundless Bio and Serapha Bio Announce Merger Agreement and $230 Million Concurrent Private Pla...Boundless Bio and Serapha Bio Announce Merger Agreement and $230 Million Concurrent Private Placement8-K7.012026-06-23
To the extent required by this Item, the information included in Item 1.01 of this Current Repo...To the extent required by this Item, the information included in Item 1.01 of this Current Report on Form 8-K is incorporated herein by ref...8-K5.022026-06-23
To the extent required by this Item, the information included in Item 1.01 of this Current Repo...To the extent required by this Item, the information included in Item 1.01 of this Current Report on Form 8-K is incorporated herein by ref...8-K5.012026-06-23
To the extent required by this Item, the information included in Item 1.01 of this Current Repo...To the extent required by this Item, the information included in Item 1.01 of this Current Report on Form 8-K is incorporated herein by ref...8-K3.022026-06-23

Live data loads in the app

This static page shell gives search engines reliable page context. Current tables, filings, charts, and market data continue to load from Finoriq APIs after the application starts.